195 related articles for article (PubMed ID: 21284136)
1. The cost-effectiveness of aripiprazole as adjunctive therapy in major depressive disorder: Thai economic model.
Leelahanaj T
J Med Assoc Thai; 2010 Nov; 93 Suppl 6():S43-50. PubMed ID: 21284136
[TBL] [Abstract][Full Text] [Related]
2. Switching to sertraline or venlafaxine after failure of SSRIs treatment in major depressive disorder: an economic evaluation of the STAR*D trial.
Leelahanaj T
J Med Assoc Thai; 2012 May; 95 Suppl 5():S29-37. PubMed ID: 22934442
[TBL] [Abstract][Full Text] [Related]
3. Developing thai economic model to study cost-effectiveness of switching to bupropion compared to combination with bupropion after the failure of an SSRI for major depressive disorder.
Leelahanaj T
J Med Assoc Thai; 2010 Nov; 93 Suppl 6():S35-42. PubMed ID: 21284135
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of adjunctive therapy with atypical antipsychotics for acute treatment of major depressive disorder.
Taneja C; Papakostas GI; Jing Y; Baker RA; Forbes RA; Oster G
Ann Pharmacother; 2012 May; 46(5):642-9. PubMed ID: 22550279
[TBL] [Abstract][Full Text] [Related]
5. Aripiprazole augmentation in major depressive disorder: a double-blind, placebo-controlled study in patients with inadequate response to antidepressants.
Berman RM; Fava M; Thase ME; Trivedi MH; Swanink R; McQuade RD; Carson WH; Adson D; Taylor L; Hazel J; Marcus RN
CNS Spectr; 2009 Apr; 14(4):197-206. PubMed ID: 19407731
[TBL] [Abstract][Full Text] [Related]
6. A double-blind, placebo-controlled study of aripiprazole adjunctive to antidepressant therapy among depressed outpatients with inadequate response to prior antidepressant therapy (ADAPT-A Study).
Fava M; Mischoulon D; Iosifescu D; Witte J; Pencina M; Flynn M; Harper L; Levy M; Rickels K; Pollack M
Psychother Psychosom; 2012; 81(2):87-97. PubMed ID: 22286203
[TBL] [Abstract][Full Text] [Related]
7. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study.
Berman RM; Marcus RN; Swanink R; McQuade RD; Carson WH; Corey-Lisle PK; Khan A
J Clin Psychiatry; 2007 Jun; 68(6):843-53. PubMed ID: 17592907
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of adjunctive aripiprazole in major depressive disorder in older patients: a pooled subpopulation analysis.
Steffens DC; Nelson JC; Eudicone JM; Andersson C; Yang H; Tran QV; Forbes RA; Carlson BX; Berman RM
Int J Geriatr Psychiatry; 2011 Jun; 26(6):564-72. PubMed ID: 20827794
[TBL] [Abstract][Full Text] [Related]
9. Adjunctive aripiprazole in major depressive disorder: analysis of efficacy and safety in patients with anxious and atypical features.
Trivedi MH; Thase ME; Fava M; Nelson CJ; Yang H; Qi Y; Tran QV; Pikalov A; Carlson BX; Marcus RN; Berman RM
J Clin Psychiatry; 2008 Dec; 69(12):1928-36. PubMed ID: 19192475
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of brexpiprazole adjunctive treatment for major depressive disorder.
Sussman M; Yu J; Kamat SA; Hartry A; Legacy S; Duffy R; Aigbogun MS
J Affect Disord; 2017 Jan; 207():54-62. PubMed ID: 27693466
[TBL] [Abstract][Full Text] [Related]
11. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study.
Marcus RN; McQuade RD; Carson WH; Hennicken D; Fava M; Simon JS; Trivedi MH; Thase ME; Berman RM
J Clin Psychopharmacol; 2008 Apr; 28(2):156-65. PubMed ID: 18344725
[TBL] [Abstract][Full Text] [Related]
12. Adjunctive aripiprazole for depression: predictive value of early assessment.
Muzina DJ; Chambers JS; Camacho TA; Eudicone JM; Forbes RA; Berman RM; Baker RA
Am J Manag Care; 2011 Dec; 17(12):793-801. PubMed ID: 22216750
[TBL] [Abstract][Full Text] [Related]
13. Effect of symptom severity on efficacy and safety of aripiprazole adjunctive to antidepressant monotherapy in major depressive disorder: a pooled analysis.
Stewart TD; Hatch A; Largay K; Sheehan JJ; Marler SV; Berman RM; Nelson JC
J Affect Disord; 2014 Jun; 162():20-5. PubMed ID: 24766999
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of adjunctive aripiprazole in patients with major depressive disorder whose symptoms worsened with antidepressant monotherapy.
Nelson JC; Rahman Z; Laubmeier KK; Eudicone JM; McQuade RD; Berman RM; Marcus RN; Baker RA; Sheehan JJ
CNS Spectr; 2014 Dec; 19(6):528-34. PubMed ID: 24642260
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of adjunctive aripiprazole in patients with major depressive disorder who showed minimal response to initial antidepressant therapy.
Nelson JC; Thase ME; Bellocchio EE; Rollin LM; Eudicone JM; McQuade RD; Marcus RN; Berman RM; Baker RA
Int Clin Psychopharmacol; 2012 May; 27(3):125-33. PubMed ID: 22466058
[TBL] [Abstract][Full Text] [Related]
16. The effectiveness and safety of adjunctive aripiprazole in Taiwanese patients with antidepressant-refractory major depressive disorder: a prospective, open-label trial.
Chen SJ; Hsiao YL; Shen TW; Chen ST
J Clin Psychopharmacol; 2012 Feb; 32(1):56-60. PubMed ID: 22198444
[TBL] [Abstract][Full Text] [Related]
17. Response and remission rates with adjunctive aripiprazole in patients with major depressive disorder who exhibit minimal or no improvement on antidepressant monotherapy.
Casey DE; Laubmeier KK; Eudicone JM; Marcus R; Berman RM; Rahman Z; Sheehan J
Int J Clin Pract; 2014 Nov; 68(11):1301-8. PubMed ID: 25196314
[TBL] [Abstract][Full Text] [Related]
18. Cost effectiveness of adjunctive quetiapine fumarate extended-release tablets with mood stabilizers in the maintenance treatment of bipolar I disorder.
Woodward TC; Tafesse E; Quon P; Lazarus A
Pharmacoeconomics; 2010; 28(9):751-64. PubMed ID: 20623994
[TBL] [Abstract][Full Text] [Related]
19. Global benefit-risk analysis of adjunctive aripiprazole in the treatment of patients with major depressive disorder.
Wisniewski SR; Chen CC; Kim E; Kan HJ; Guo Z; Carlson BX; Tran QV; Pikalov A
Pharmacoepidemiol Drug Saf; 2009 Oct; 18(10):965-72. PubMed ID: 19662630
[TBL] [Abstract][Full Text] [Related]
20. Augmentation of aripiprazole for depressed patients with an inadequate response to antidepressant treatment: a 6-week prospective, open-label, multicenter study.
Jon DI; Kim DH; Seo HJ; Kwon YJ; Kim MD; Yang JC; Suh HS; Min KJ; Pae CU; Bahk WM
Clin Neuropharmacol; 2013; 36(5):157-61. PubMed ID: 24045606
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
